The "Medical Insurance Negotiation" in the United States is about to land, stinging the nerves of the old MNC, will drug innovation be affected?

On the other side of the ocean, the US version of the "Medical Insurance Price Negotiation" has settled

Taking the lead in targeting "old medicine", the old MNC is deeply affected

Taking the lead in targeting "old medicine", the old MNC is deeply affected

Under the Act, price negotiations will be implemented in four stages over several years

The thresholds for participating in the negotiation are: small-molecule drugs that have not been impacted by generic drugs (similar drugs) and have been on the market for 7 years, or large-molecule drugs that have been on the market for 13 years

For innovative drugs with an approval period of 12-16 years, the negotiated price ceiling is 65% of the average price;

For innovative drugs approved for more than 16 years, the negotiated price ceiling is 40% of the average price

In addition, Medicare medical insurance is divided into 4 parts, Part A is hospitalization insurance, Part B is supplementary medical insurance, Part C is medical insurance advantage plan, and Part D is prescription drug plan

The 10 highest-priced prescription drugs in Medicare Part D are negotiated

According to the forecast of Bank of America analysts, BMS' apixaban and O drugs, Johnson & Johnson's rivaroxaban, Merck's sitagliptin and K drugs, AbbVie's ibrutinib, Regeneron's aflibercept , Amgen's denosumab, etc.

Apixaban O-drug Rivaroxaban Siagliptin K-drug Ibrutinib Aflibercept

Among them, apixaban of BMS is mainly used to reduce the risk of stroke and systemic embolism.

BMS' PD-1 product O drug is also a part B product with potential negotiation risks.

Since this bill is mainly aimed at heavyweight categories, the impact on the old MNC can be said to be strong

Save the federal government $99 billion over 10 years

Executives from Gilead Sciences, Johnson & Johnson, Novartis, AbbVie and other companies have expressed concerns about the drug pricing plans being developed during the second-quarter earnings conference calls over the past two weeks

After China's innovative drugs are difficult to go overseas, will their commercialization be affected?

After China's innovative drugs are difficult to go overseas, will their commercialization be affected?

As one of the countries with the highest prescription drug prices in the world, successive U.

A key factor in the high drug prices in the United States is that insurers and drug companies conduct one-on-one individual bargaining

In early June, several researchers from Harvard Medical School jointly released the research report "Trends in Prescription Drug Pricing 2008-2021".

The average annual growth of new drug listing prices is 20.

Taking PD-1 as an example, although domestic PD-1 monoclonal antibodies have been intensively seeking to go overseas in the past two years, many major indications will require a longer period of time to complete additional clinical trials for the American population

Take PD-1 as an example

Curb innovation, or exaggerate?

Curb innovation, or exaggerate?

Over the years, the U.

Therefore, the American pharmaceutical industry organization (American Pharmaceutical Research and Manufacturers Association) and many pharmaceutical companies have expressed their dissatisfaction with the implementation of the Act.
They believe that the implementation of the Act will affect the enthusiasm of pharmaceutical companies in the research and development of innovative drugs, resulting in Fewer treatments and complete cures will not improve access to and affordability of medicines for Americans
.
The introduction of this bill pushed biomedical research into a dark age, a tragic loss for patients
.

However, according to the Congressional Budget Office (CBO), from 2020 to 2029, the number of original research drugs on the US market will decrease by 8, and in the following years, there will be a total of more than 30 reductions
.
However, Bank of America and UBS believe the bill is unlikely to have a material impact on the U.
S.
pharmaceutical industry
.

In the end, it remains to be seen whether the "Act" will have an impact on the innovative drug ecosystem in the United States, and to what extent
.
But what is certain is that the advancement of the "Act" has become more chilly for Chinese pharmaceutical companies
.

Disclaimer: This article is for information sharing only and does not represent the position and opinion of Insight, nor does it recommend or introduce treatment options
.
If necessary, please consult and contact regular medical institutions
.

Disclaimer: This article is for information sharing only and does not represent the position and opinion of Insight, nor does it recommend or introduce treatment options
.
If necessary, please consult and contact regular medical institutions
.
Disclaimer:

References:

References: References:

1.
Novo Nordisk, Roche see outsized threats from US drug pricing talks: analysts | Fierce Pharma;

1.
Novo Nordisk, Roche see outsized threats from US drug pricing talks: analysts | Fierce Pharma; 1.
Novo Nordisk, Roche see outsized threats from US drug pricing talks: analysts | Fierce Pharma;

2.
President Biden Announces Prescription Drug Pricing Plan in Build Back Better Framework | The White House;

2.
President Biden Announces Prescription Drug Pricing Plan in Build Back Better Framework | The White House; 2.
President Biden Announces Prescription Drug Pricing Plan in Build Back Better Framework | The White House;

3.
Harvard, Kesselheim paper highlights almost 90x increase in launch prices for new drugs since 2008 – Endpoints News (endpts.
com).

3.
Harvard, Kesselheim paper highlights almost 90x increase in launch prices for new drugs since 2008 – Endpoints News (endpts.
com).
3.
Harvard, Kesselheim paper highlights almost 90x increase in launch prices for new drugs since 2008 – Endpoints News (endpts .
com).